NAS:JNCE (USA)
Business Description
Jounce Therapeutics Inc
NAICS : 325412
SIC : 2834
780 Memorial Drive, Cambridge, MA, USA, 02139
Compare
Compare
Traded in other countries / regions
21J.Germany
•
JNCE.USA
Description
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company has developed a suite of integrated technologies that comprise a Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.5 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | -6.27 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -35.4 | |||||
3-Year EBITDA Growth Rate | -28 | |||||
3-Year EPS without NRI Growth Rate | -29.4 | |||||
3-Year FCF Growth Rate | 5.6 | |||||
3-Year Book Growth Rate | 11.4 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 93.23 | |||||
9-Day RSI | 85.04 | |||||
14-Day RSI | 76.67 | |||||
6-1 Month Momentum % | -58.58 | |||||
12-1 Month Momentum % | -33.96 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.78 | |||||
Quick Ratio | 6.78 | |||||
Cash Ratio | 6.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.9 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -59.62 | |||||
ROA % | -52.79 | |||||
ROIC % | -213.24 | |||||
ROC (Joel Greenblatt) % | -602.9 | |||||
ROCE % | -57.21 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.72 | |||||
PB Ratio | 1.3 | |||||
Price-to-Tangible-Book | 1.58 | |||||
EV-to-EBIT | -1.12 | |||||
EV-to-EBITDA | -1.14 | |||||
EV-to-Revenue | 4.41 | |||||
EV-to-Forward-Revenue | 1.99 | |||||
EV-to-FCF | -1.21 | |||||
Price-to-Net-Current-Asset-Value | 1.98 | |||||
Price-to-Net-Cash | 2.12 | |||||
Earnings Yield (Greenblatt) % | -91.05 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:JNCE
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -2.55 | ||
Beta | 0.35 | ||
Volatility % | 59.85 | ||
14-Day RSI | 76.67 | ||
14-Day ATR ($) | 0.308862 | ||
20-Day SMA ($) | 3.46 | ||
12-1 Month Momentum % | -33.96 | ||
52-Week Range ($) | 2.76 - 9.81 | ||
Shares Outstanding (Mil) | 51.69 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Jounce Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |